# Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.

> **NCT02681991** · PHASE4 · COMPLETED · sponsor: **Daewon Pharmaceutical Co., Ltd.** · enrollment: 110 (actual)

## Conditions studied

- Chronic Renal Failure

## Interventions

- **DRUG:** Renamezin capsule

## Key facts

- **NCT ID:** NCT02681991
- **Lead sponsor:** Daewon Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681991, "Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02681991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*